Moreover, miR-181, which acts as a regulator for B-cell differentiation, is decreased in CLL, leading to an upregulation of the target proteins MCL1 and BCL2, which will induce resistance to treatment [63]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.